RTP Mobile Logo
Current Controversies, Recent Developments and Emerging Strategies in the Practical Management of Prostate Cancer
Released January 2013

Roundtable participants include Drs Tomasz M Beer, Robert Dreicer, Mario A Eisenberger, William K Oh, Daniel P Petrylak, A Oliver Sartor, Susan F Slovin and Matthew R Smith. (Audio Content)

CE Disclosures and Faculty Information

  • OVERVIEW OF ACTIVITY

    Prostate cancer is the most frequently diagnosed cancer in men, with an estimated 241,740 new cases in 2012 in the United States. Although virtually all locally advanced or metastatic sites of tumor are initially reliant on androgen stimulation for growth and respond to treatment with androgen deprivation therapy, inevitably resistance to hormone blockade eventually develops, culminating in the recurrence of highly aggressive castration-resistant prostate cancer (CRPC). Recently published randomized controlled studies focused specifically on this population have led to the emergence of novel therapeutic strategies for patients with CRPC and resulted in a paradigm shift to the multidisciplinary care of this disease. A number of pivotal data sets illustrating the benefits of several novel agents indicate that additional therapeutic options may soon be available that will warrant consideration and integration into prostate cancer care. The treatment landscape and available options for prostate cancer have thus broadened, making choices more challenging for many healthcare professionals and patients, and a once-stagnant systemic treatment algorithm, largely confined to medical or surgical castration, has evolved into delivery of cutting-edge antineoplastic therapy necessitating learning opportunities for urologists and medical oncologists. This CME program uses a roundtable discussion with leading prostate cancer clinical investigators to assist practicing clinicians in formulating up-to-date and appropriate clinical management strategies.

    LEARNING OBJECTIVES

    • Explore the emerging data and active research evaluating novel agents — including radiopharmaceuticals, androgen biosynthesis inhibitors, antiandrogens and clusterin antisense oligonucleotides — in the setting of advanced prostate cancer, and discuss the biologic basis for their clinical activity.
    • Recall existing and emerging research demonstrating the effects of secondary hormonal interventions on quality and quantity of life for patients with chemotherapy-naïve and chemotherapy-pretreated CRPC, and use this information to guide treatment planning for these patients.
    • Efficiently identify and educate patients with skeletal metastases about the efficacy and safety of emerging systemic bone-directed treatments.
    • Employ case-based learning to effectively apply evidence-based research findings in the determination of best-practice sequencing of available systemic agents for patients with metastatic prostate cancer.
    • Counsel appropriately selected patients with minimally symptomatic or asymptomatic advanced prostate cancer about sipuleucel-T as a treatment option, and define an approach to patient monitoring after treatment with this agent.
    ACCREDITATION STATEMENT

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CREDIT DESIGNATION STATEMENT

    Research To Practice designates this enduring material for a maximum of 2.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    HOW TO USE THIS CME ACTIVITY

    This CME activity contains both audio and print components. To receive credit, the participant should review the CME information, listen to the CDs, review the monograph, complete the Post-test with a score of 70% or better and fill out the Educational Assessment and Credit Form located in the back of this monograph or on our website at ResearchToPractice.com/PCUTT112/CME. The text portion of this activity contains edited comments, clinical trial schemas, graphics and references that supplement the audio MP3s, as well as links to relevant full-text articles, abstracts, trial information and other web resources.

    CONTENT VALIDATION AND DISCLOSURES

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTYDr Slovin had no real or apparent conflicts of interest to disclose. The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process: Dr BeerConsulting Agreements: Dendreon Corporation, GTx Inc; Paid Research: Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Cell Therapeutics Inc, Cougar Biotechnology Inc, Dendreon Corporation, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Medivation Inc, Novartis Pharmaceuticals Corporation, OncoGenex Pharmaceuticals Inc; Speakers Bureau: Sanofi. Dr DreicerAdvisory Committee: EMD Serono Inc, Janssen Pharmaceuticals Inc, Lilly USA LLC, Millennium: The Takeda Oncology Company, Novartis Pharmaceuticals Corporation. Dr EisenbergerAdvisory Committee: Sanofi; Consulting Agreements: Bristol-Myers Squibb Company, Millennium: The Takeda Oncology Company; Paid Research: Genentech BioOncology, Sanofi. Dr OhConsulting Agreements: Amgen Inc, Astellas, Bayer HealthCare Pharmaceuticals, Bellicum Pharmaceuticals Inc, Dendreon Corporation, Janssen Pharmaceuticals Inc, Medivation Inc, Pfizer Inc, Sanofi; Paid Research: Millennium: The Takeda Oncology Company. Dr PetrylakAdvisory Committee: Amgen Inc, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Millennium: The Takeda Oncology Company, Sanofi; Consulting Agreement: Celgene Corporation; Paid Research: Boehringer Ingelheim Pharmaceuticals Inc, Celgene Corporation, Eisai Inc, GlaxoSmithKline, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Lilly USA LLC, Millennium: The Takeda Oncology Company, Sanofi. Dr SartorAdvisory Committee: Sanofi; Clinical Investigator: AstraZeneca Pharmaceuticals LP, EMD Serono Inc, Millennium: The Takeda Oncology Company, Sanofi; Consulting Agreements: Algeta ASA, Amgen Inc, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Celgene Corporation, GlaxoSmithKline, Medivation Inc, Millennium: The Takeda Oncology Company, OncoGenex Pharmaceuticals Inc, Pfizer Inc, Sanofi, Teva Oncology. Dr SmithAdvisory Committee and Consulting Agreements: Amgen Inc, Bayer HealthCare Pharmaceuticals, Millennium: The Takeda Oncology Company; Paid Research: Amgen Inc, Millennium: The Takeda Oncology Company.

    MODERATORDr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: Abbott Laboratories, Allos Therapeutics, Amgen Inc, ArQule Inc, Astellas, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Biodesix Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Foundation Medicine Inc, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Incyte Corporation, Lilly USA LLC, Medivation Inc, Merck, Millennium: The Takeda Oncology Company, Mundipharma International Limited, Novartis Pharmaceuticals Corporation, Onyx Pharmaceuticals Inc, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Spectrum Pharmaceuticals Inc and Teva Oncology.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.


    This activity is supported by educational grants from Astellas/Medivation Inc, Dendreon Corporation, Millennium: The Takeda Oncology Company, Sanofi and Teva Oncology.


    Hardware/Software Requirements:
    A high-speed Internet connection  
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
    Adobe Flash Player 10.2 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: January 2013
    Expiration date: January 2014

    After completing the Post-test, learners may download and review the answers here in order to identify further areas of study.

Acknowledge and close

Listen to audio:
Current Controversies, Recent Developments and Emerging Strategies in the Practical Management of Prostate Cancer
Released January 2013

Roundtable participants include Drs Tomasz M Beer, Robert Dreicer, Mario A Eisenberger, William K Oh, Daniel P Petrylak, A Oliver Sartor, Susan F Slovin and Matthew R Smith. (Audio Content)

Read print: